Context

Cyclopharma, based in Clermont-Ferrand (France), specializes in radiopharmaceuticals for diagnostic imaging procedures in oncology, cardiology and neurology.

The company anticipates revenues of EUR25 million and holds a leading market share in France. It operates seven production and R&D sites in France with more than 110 employees.

Cyclopharma was acquired by Olivier and the Denos Group in 2013. Other significant shareholders include BPI France, Sofimac and Crédit Agricole.

Cyclopharma is purchased by Curium, which was formed through the merger of IBA Molecular and Mallinckrodt’s nuclear imaging activities and is backed by the UK mid-market private equity firm, CapVest.

About Cyclopharma

Since its creation in 2000, Cyclopharma has developed molecular imaging solutions to allow the observation of cell function in vivo as part of the targeted treatment of cancer, in order to improve individualized treatment plans for patients in terms of diagnostics, monitoring and therapeutic effectiveness, whilst also reducing costs. With more than 110 employees and revenue of EUR23 million, Cyclopharma invests more than 10% of revenue in research into novel molecular imaging tracers. Since 2015 it has built on dense and balanced geographical coverage to drive international growth, with the aim of becoming a major European force in personalized medicine.

About Curium Pharma

Curium is a world-class nuclear medicine solutions provider with more than a century of industry experience. Formed by the union of IBA Molecular and Mallinckrodt Nuclear Medicine LLC, Curium is the largest vertically integrated radiopharmaceutical product manufacturer in the industry. With more than 50 manufacturing facilities across Europe and the United States, Curium supports over 14 million patients around the world with SPECT, PET, and therapeutic radiopharmaceuticals to provide potentially life-saving diagnostic solutions. Curium’s products are currently commercialized in more than 60 countries across the globe.

Discover Curium Pharma

Hervé Ronin

Investment Banking

Dr. Mickael Dubourd

Investment Banking

Romain Ellul

Investment Banking

Deal Team

Should you want to know more about this transaction, you can contact one of the team members above

Privacy Preference Center